Who Should Get PRRT?

Who Should Get PRRT?

243 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Soulen - Who Should Get PRRT Weighing Cumulative Toxicity Key to PRRT Treatment

Michael C. Soulen, MD of the University of Pennsylvania answers the question "Who Should Get PRRT?". He summarizes that you must weigh cumulative toxicity which may be key to PRRT (Peptide Receptor Radionuclide Therapy) treatment from ASCO GI 2018.
Up Next Autoplay
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
0 Views
cancergrace 1 day
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
0 Views
Cancer-News 2 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 2 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 2 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
0 Views
Massachusetts General Hospital 2 days
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Why was NINLARO compared to a placebo in TOURMALINE-MM4?
Category: Multiple Myeloma
0 Views
Cancer-News 2 days
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
ONC201 Recurrent Glioblastoma: How Can We Get Access to This Drug?
Category: Brain Cancer
4 Views
Massachusetts General Hospital 2 days